Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 5/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.31 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31169611 | 1.00 | BTK (0.44) | BTKHDAC2HDAC1GRIN2BMAPK1 | |
| SCHEMBL21408909 | 0.83 | HDAC2 (0.36) | BTKHDAC2HDAC1GRIN2BNTRK1 | |
| SCHEMBL21408845 | 0.83 | HDAC2 (0.36) | BTKHDAC2HDAC1GRIN2BNTRK1 | |
| SCHEMBL21408852 | 0.83 | HDAC2 (0.36) | BTKHDAC2HDAC1GRIN2BNTRK1 | |
| SCHEMBL21408900 | 0.83 | HDAC2 (0.36) | BTKHDAC2HDAC1GRIN2BNTRK1 | |
| SCHEMBL27003888 | 0.79 | HDAC2 (0.34) | BTKHDAC2HDAC1 | |
| SCHEMBL17770661 | 0.76 | CXCR2 (0.34) | BTK | |
| SCHEMBL13765546 | 0.75 | RBP4 (0.38) | BTKGRIN2BKDM4E | |
| SCHEMBL23120602 | 0.74 | S1PR2 (0.34) | HDAC2HDAC1MAPK1KDM4E | |
| SCHEMBL27426152 | 0.74 | HDAC2 (0.34) | BTKHDAC2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2025-02-06 | — | — | US | disclosed |
| EP-4428130-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | Ubix Therapeutics, Inc. (KR) | 2024-09-11 | — | — | EP | disclosed |
| CN-118159532-A | Compound with BTK protein degradation activity and medical application thereof | 尤比克斯治疗公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2023080732-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | 주식회사 유빅스테라퓨틱스 | 2023-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | BTK, LYN, SYK | BTK 1/4885HDAC2 984/4885HDAC1 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.